Detalhe da pesquisa
1.
The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib.
Oncology
; 101(8): 491-501, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37429266
2.
Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study.
BMC Gastroenterol
; 23(1): 222, 2023 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37380950
3.
Usefulness of Acetic Acid Spray with Narrow-Band Imaging for Identifying the Margin of Sessile Serrated Lesions.
Dig Dis Sci
; 68(6): 2553-2560, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36609732
4.
Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices.
BMC Gastroenterol
; 22(1): 535, 2022 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36550416
5.
Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma.
Cancer Med
; 13(5): e7025, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38477514
6.
Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma-Consideration of the Locations of Target Lesions.
Cancers (Basel)
; 15(3)2023 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36765804
7.
Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Liver Cancer
; 12(3): 251-261, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37601981
8.
Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma.
Intern Med
; 62(12): 1771-1774, 2023 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36328580
9.
Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein.
Cancers (Basel)
; 15(8)2023 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37190231
10.
Clinical Outcomes of Switching from Zoledronic Acid to Denosumab for the Management of Severe Bone Metastasis from Hepatocellular Carcinoma: A Single-Center, Open-Label, Prospective Intervention Trial.
Yonago Acta Med
; 66(4): 422-431, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-38028262
11.
Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Cancers (Basel)
; 15(22)2023 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38001666
12.
Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene.
Case Rep Gastroenterol
; 16(1): 110-115, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35431768
13.
Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection.
J Gastroenterol
; 57(9): 676-683, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35849192
14.
The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment.
PLoS One
; 17(1): e0262675, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35041693
15.
Analysis of Lenvatinib's Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma.
Cancers (Basel)
; 14(20)2022 Oct 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36291850
16.
Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma.
Cancers (Basel)
; 14(2)2022 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35053484
17.
Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
Medicine (Baltimore)
; 100(42): e27576, 2021 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34678902
18.
Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice.
Cancers (Basel)
; 13(16)2021 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34439111
19.
Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Liver Cancer
; 11(2): 174-177, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35634428